Drug Patents owned by Azurity

1. List of Edarbi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(1 year, 11 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(5 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBI before it's patent expiration?
More Information on Dosage

2. List of Edarbyclor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(1 year, 11 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(5 years from now)

US9169238 AZURITY Solid pharmaceutical composition
Feb, 2030

(7 years from now)

US9387249 AZURITY Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Jul, 2031

(8 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's patent expiration?
More Information on Dosage

3. List of Epaned drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173141 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10039745 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US9808442 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10154987 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10786482 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US9669008 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10772868 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US11040023 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US11141405 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Method of treatment of heart failure; Treatment of heart failure; Method of treating hypertension; Method of treating left ventricular dysfunction; Treatment of hypertension

Dosage: SOLUTION;ORAL

How can I launch a generic of EPANED before it's patent expiration?
More Information on Dosage

4. List of Eprontia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(17 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; Indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION;ORAL

How can I launch a generic of EPRONTIA before it's patent expiration?
More Information on Dosage

5. List of Firvanq Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959949 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10959947 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10959948 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of c. difficile-associated diarrhea; Treatment of staphylococcal enterocolitis

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of FIRVANQ KIT before it's patent expiration?
More Information on Dosage

6. List of Fleqsuvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's patent expiration?
More Information on Dosage

7. List of Horizant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8048917 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Nov, 2022

(2 months ago)

US6818787 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(2 years from now)

US8026279 AZURITY Crystalline form of γ-aminobutyric acid analog
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034 AZURITY Crystalline form of γ-aminobutyric acid analog
Jan, 2025

(1 year, 11 months from now)

US8114909 AZURITY Treating or preventing restless legs syndrome using prodrugs of GABA analogs
Apr, 2026

(3 years from now)

US8795725 AZURITY GABA analog prodrug sustained release oral dosage forms
Jun, 2029

(6 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Market Authorisation Date: 06 April, 2011

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HORIZANT before it's patent expiration?
More Information on Dosage

8. List of Katerzia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364230 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US11484498 AZURITY NA
Oct, 2037

(14 years from now)

US10959991 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US11471409 AZURITY NA
Oct, 2037

(14 years from now)

US10952998 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10894039 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10695329 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10799453 AZURITY Amlodipine formulations
Apr, 2039

(16 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: Angina pectoris; Angina; A method of treating coronary artery disease; A method of treating hypertension; Treatment of hypertension; Method of treating hypertension

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's patent expiration?
More Information on Dosage

9. List of Konvomep drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751333 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(16 years from now)

US11103492 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(16 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

10. List of Nymalize drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581 AZURITY Dispenser for medicaments and method and apparatus for making same
Jun, 2023

(4 months from now)

US8517997 AZURITY Dispenser for medicaments and method and apparatus for making same
May, 2024

(1 year, 3 months from now)

US11517563 AZURITY NA
Apr, 2038

(15 years from now)

US11207306 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

US10576070 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

US10342787 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

US11413277 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms

Dosage: SOLUTION;ORAL

How can I launch a generic of NYMALIZE before it's patent expiration?
More Information on Dosage

11. List of Qbrelis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814751 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10039800 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Treatment of myocardial infarction; Method of treating hypertension; Treatment of heart failure; Method of treatment of heart failure; Reduction of mortality in acute myocardial infarction; Treatment of hypertension; Acute myocardial infarction

Dosage: SOLUTION;ORAL

How can I launch a generic of QBRELIS before it's patent expiration?
More Information on Dosage

12. List of Sotylize drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013703 AZURITY Sotalol compositions and uses of the same
Apr, 2034

(11 years from now)

US10206895 AZURITY Sotalol compositions and uses of the same
Apr, 2034

(11 years from now)

US9724297 AZURITY Sotalol compositions and uses of the same
Aug, 2035

(12 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2014

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening

Dosage: SOLUTION;ORAL

More Information on Dosage

13. List of Xatmep drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259427 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US10610485 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US11116724 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US10231927 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

US9855215 AZURITY Methotrexate composition
Jan, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 25, 2024

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: Treatment of juvenile rheumatoid arthritis; A method for treating acute lymphoblastic leukemia

Dosage: SOLUTION;ORAL

More Information on Dosage

14. List of Zonisade drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529333 AZURITY Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
Aug, 2038

(15 years from now)

US11478456 AZURITY NA
Aug, 2038

(15 years from now)

Drugs and Companies using ZONISAMIDE ingredient

Market Authorisation Date: 15 July, 2022

Treatment: A method of treating seizures

Dosage: SUSPENSION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic